Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
Do you have experience combining tocilizumab with mycophenolate in patients with scleroderma lung disease and inflammatory arthritis?
Related Questions
How would you manage a patient with erosive seronegative rheumatoid arthritis with IgG and IgM deficiency?
How do you approach venous insufficiency management in patients on Jak inhibitors?
Would you switch to a TNF-I if patient developed squamous cell skin cancer on Orencia after failure of MTX for seropositive RA?
What is your approach for cancer screening for elderly onset RA?
How do you approach medication management in patients with RA when transitioning from csDMARD triple therapy to anti-TNF?
How do you approach the timing of DMARD initiation in patients with active RA who are on treatment for latent TB?
Would you consider using a JAK inhibitor for a patient with RA associated scleritis?
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
How do you approach treating a patient with RA and cirrhosis who did not respond to csDMARDs?
Do you feel comfortable using Jak inhibitors in patients with a strong family history of CAD, but no other risk factors?
